Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants

Elizabeth B. Lamont, James E. Herndon, Jane C. Weeks, I. Craig Henderson, Rogerio Lilenbaum, Richard L. Schilsky, Nicholas A. Christakis, Lee S. Schwartzberg, Stephen George, Stephen Grubbs, Jeffrey Kirshner, George P. Cannelos, Marc S. Ernstoff, Jeffrey Crawford, Robert L. Comis, Edward Gelmann, H. Herbert Mauer, John W. Kugler, Placido P. Ferreira, Jonathan A. PolikoffMark Citron, Michael L. Grossbard, Mark Green, Alan P. Lyss, Rogerio Lilenbaum, Lewis Silverman, Michael J. O'Connell, Daniel R. Budman, William Sikov, Ellis Levine, Jack Goldberg, James N. Atkins, John Ellerton, Charles Coltman, Arnold D. Rubin, Stephen L. Graziano, Jeffrey Kirshner, Clara D. Bloomfield, Robert Diasio, Stephen L. Seagren, Alan P. Venook, Gini Fleming, Lawrence Feldman, Gerald H. Clamon, Martin Edelman, F. Mary Ellen Taplin, Bruce A. Peterson, Michael C. Perry, Anne Kessinger, Thomas C. Shea, Harvey B. Niell, Lynn M. Steinbrenner, Hyman B. Muss, John D. Roberts, David D. Hurd, Joseph J. Drabeek, Nancy Bartlett, Scott Wadler

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treated in two Cancer and Leukemia Group B (CALGB) breast and lung cancer trials (i.e., 45 from trial 9344 and 130 from trial 9730) with contemporaneous ambulatory and in-patient Medicare health insurance claims data from Centers for Medicare and Medicaid Services (CMS). The breast trial participants studied were those elderly enrolled between 1995 and 1997 and treated with doxorubicin and cyclophosphamide or this combination with paclitaxel. The lung trial participants studied were those elderly enrolled between 1998 and 2000 and treated with paclitaxel and carboplatin or paclitaxel alone. Comparing CALGB data with Medicare claims, we found the crude sensitivity for chemotherapy administration was 93% (95% confidence interval [CI] = 88% to 96%). Individual chemotherapy agents had similarly high sensitivities, ranging from 81% (95% CI = 70% to 89%) for carboplatin to 91% (95% CI = 79% to 98%) for cyclophosphamide. Agent-specific specificities were 100%. CMS data reliably captured repeat administration of chemotherapy to within one cycle. Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer.

Original languageEnglish (US)
Pages (from-to)1080-1083
Number of pages4
JournalJournal of the National Cancer Institute
Volume97
Issue number14
DOIs
StatePublished - Jul 20 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants'. Together they form a unique fingerprint.

  • Cite this

    Lamont, E. B., Herndon, J. E., Weeks, J. C., Henderson, I. C., Lilenbaum, R., Schilsky, R. L., Christakis, N. A., Schwartzberg, L. S., George, S., Grubbs, S., Kirshner, J., Cannelos, G. P., Ernstoff, M. S., Crawford, J., Comis, R. L., Gelmann, E., Mauer, H. H., Kugler, J. W., Ferreira, P. P., ... Wadler, S. (2005). Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants. Journal of the National Cancer Institute, 97(14), 1080-1083. https://doi.org/10.1093/jnci/dji189